Article
Inflammation-related genetic variations and survival in patients with advanced non-small cell lung cancer receiving first-line chemotherapy.
Clinical pharmacology and therapeutics - 1 Sept 2014
Pu Xia, Hildebrandt Michelle A, Lu Charles, Roth Jack A, Stewart David J, Zhao Yang, Heist Rebecca S, Ye Yuanqing, Chang David W, Su Li, Minna John D, Lippman Scott M, Spitz Margaret R, Christiani David C, Wu Xifeng
Abstract excerpt
Accurate prognostic prediction is challenging for patients with advanced-stage non-small cell lung cancer (NSCLC). We systematically investigated genetic variants within inflammation pathways as potential prognostic markers for advanced-stage NSCLC patients treated with first-line chemotherapy. A discovery phase in 502 patients and an internal validation phase in 335 patients were completed at the MD Anderson...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
